<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165096</url>
  </required_header>
  <id_info>
    <org_study_id>3475-01C</org_study_id>
    <secondary_id>MK-3475-01C</secondary_id>
    <secondary_id>KEYMAKER-U01C</secondary_id>
    <secondary_id>2020-001629-29</secondary_id>
    <nct_id>NCT04165096</nct_id>
  </id_info>
  <brief_title>KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)</brief_title>
  <official_title>KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in&#xD;
      combination with MK-5890 or MK-4830 in participants with advanced squamous or non-squamous&#xD;
      NSCLC that have been previously treated with anti-PD-L1 therapy.&#xD;
&#xD;
      This study is one of three pembrolizumab substudies being conducted under one pembrolizumab&#xD;
      umbrella master protocol (MK-3475-U01/KEYMAKER-U01).&#xD;
&#xD;
      Enrollment in the pembrolizumab+MK-5890 arm has been completed with Amendment 4.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The master screening protocol is MK-3475-U01 (KEYMAKER-U01) - NCT04165798&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">February 13, 2032</completion_date>
  <primary_completion_date type="Anticipated">February 13, 2032</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>PFS is defined as the time from first dose of study treatment until either the earliest date of documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience One or More Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 27 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + MK-5890</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-5890 IV for a maximum of 35 cycles (approximately 2 years). All participants are premedicated 1.5 hours (±30 minutes) before infusion of MK-5890 with 50 mg oral (PO) diphenhydramine (or equivalent dose of antihistamine) and 500-1000 mg of acetaminophen PO (or equivalent dose of analgesic).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab + MK-4830</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-4830 IV for a maximum of 35 cycles (approximately 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab + MK-0482</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each 3-week cycle, participants receive pembrolizumab 200 mg intravenously (IV) PLUS MK-0482 IV for a maximum of 35 cycles (approximately 2 years).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab + MK-0482</arm_group_label>
    <arm_group_label>Pembrolizumab + MK-4830</arm_group_label>
    <arm_group_label>Pembrolizumab + MK-5890</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-5890</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab + MK-5890</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-4830</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab + MK-4830</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diphenhydramine</intervention_name>
    <description>PO</description>
    <arm_group_label>Pembrolizumab + MK-5890</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen</intervention_name>
    <description>PO</description>
    <arm_group_label>Pembrolizumab + MK-5890</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-0482</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab + MK-0482</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Has a histologically- or cytologically-confirmed diagnosis of Stage IV squamous or&#xD;
             non-squamous NSCLC&#xD;
&#xD;
          -  Has non-squamous NSCLC and is not eligible for an approved targeted therapy&#xD;
&#xD;
          -  Is able to provide archival tumor tissue sample collected either within 5 years or&#xD;
             within the interval from completion of last treatment but before entering the&#xD;
             screening period or newly obtained core or excisional biopsy of a tumor lesion not&#xD;
             previously irradiated obtained within 90 days of treatment initiation&#xD;
&#xD;
          -  Have progressed on treatment with an anti-PD-(L)1 monoclonal antibody (mAb)&#xD;
             administered either as monotherapy, or in combination with other checkpoint inhibitors&#xD;
             or other therapies&#xD;
&#xD;
          -  Have progressive disease (PD) during/after platinum doublet chemotherapy&#xD;
&#xD;
          -  Is able to complete all screening procedures within the 35-day screening window&#xD;
&#xD;
          -  Male participants must agree to use contraception and refrain from donating sperm&#xD;
             during the treatment period and for at least 120 days after the last dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Female participants must not be pregnant or breastfeeding, and at least one of the&#xD;
             following conditions apply:&#xD;
&#xD;
               1. Not a woman of childbearing potential (WOCBP) OR&#xD;
&#xD;
               2. A WOCBP who agrees to use contraception during the treatment period and for at&#xD;
                  least 120 days after the last dose of study treatment&#xD;
&#xD;
          -  Has adequate organ function within 10 days of initiation of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of small cell lung cancer&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days before the first dose of study treatment&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 2 years&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in the past 2&#xD;
             years&#xD;
&#xD;
          -  Has a history of (noninfectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has clinically significant cardiac disease, including unstable angina, acute&#xD;
             myocardial infarction within 6 months from Day 1 of study treatment, or New York Heart&#xD;
             Association Class III or IV congestive heart failure&#xD;
&#xD;
          -  Has a known history of Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperating with the requirements of the study&#xD;
&#xD;
          -  Has had major surgery &lt;3 weeks before the first dose of study treatment&#xD;
&#xD;
          -  Has received prior radiation therapy to the lung that is &gt;30 Gray (Gy) within 6 months&#xD;
             of the first dose of study treatment&#xD;
&#xD;
          -  Has received a live vaccine within 30 days before the first dose of study treatment.&#xD;
             Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is&#xD;
             allowed as long as they are messenger ribonucleic acid (mRNA) vaccines, adenoviral&#xD;
             vaccines, or inactivated vaccines. Investigational vaccines (ie, those not licensed or&#xD;
             approved for Emergency Use) are not allowed&#xD;
&#xD;
          -  Has received any prior immunotherapy and was discontinued from that treatment due to a&#xD;
             severe or worse immune-related adverse event (irAE)&#xD;
&#xD;
          -  Has had chemotherapy or biological cancer therapy within 4 weeks before the first dose&#xD;
             of study treatment or has not recovered to Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) Grade 1 or better from the AEs due to cancer therapeutics administered&#xD;
             more than 4 weeks before the first dose of study treatment (including participants who&#xD;
             had previous immunomodulatory therapy with residual irAEs)&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks before the first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  Has participated in Substudies 1 or 2&#xD;
&#xD;
          -  Has had a severe hypersensitivity reaction to treatment with monoclonal antibodies&#xD;
             (including pembrolizumab) and/or any of their excipients&#xD;
&#xD;
          -  Is pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of study treatment&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center ( Site 0001)</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-256-3425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope ( Site 0014)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>626-218-9200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco ( Site 0007)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-885-7820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University ( Site 0036)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-444-2223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Markey Cancer Center ( Site 0019)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>859-218-0131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Franklin Square Medical Center ( Site 0033)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-777-7364</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ( Site 0003)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-724-4000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute ( Site 0002)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-632-4767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-691-6971</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center ( Site 0016)</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>603-650-4428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>551-996-4725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center ( Site 0034)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>929-455-2428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic ( Site 0006)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-636-6888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center ( Site 0015)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-366-0233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania ( Site 0010)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-220-9703</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center ( Site 0009)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-792-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz ( Site 0062)</name>
      <address>
        <city>Gyor</city>
        <state>Gyor-Moson-Sopron</state>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3696418244</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0061)</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 0072)</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>8457108</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97286400795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus-Oncology ( Site 0076)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+ 97247776750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center ( Site 0075)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97225645203</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center ( Site 0071)</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>4428132</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97297472414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0074)</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 0070)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235307096</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi ( Site 0173)</name>
      <address>
        <city>Florence</city>
        <state>Firenze</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393209225506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 0081)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82215883369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital ( Site 0080)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82022281004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0082)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82215993114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225463066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)</name>
      <address>
        <city>Koszalin</city>
        <state>Zachodniopomorskie</state>
        <zip>75-581</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48502204953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L Hospitalet ( Site 0090)</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34932607283</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid ( Site 0091)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914521987</phone>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death Receptor 1 (PD-1, PD1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 1 (PD-L1, PDL1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 2 (PD-L2, PDL2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

